National Biologics Manufacturing Centre launched
The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
The Centre for Process Innovation (CPI) has officially launched the new £38 million National Biologics Manufacturing Centre in Darlington, Co. Durham. The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
Biopharmaceuticals are medicines produced through biotechnology, which represent the cutting-edge The National Biologics Manufacturing Centre was announced in 2012 as part of the UK strategy for life science. The strategy outlined a vision for the UK to be a global leader in the life science sector. The £38 million investment was made by the Department for Business Innovation and Skills through InnovateUK.
Launching the new Centre, Jo Johnson MP, Minister of State for Universities and Science said: “We want the UK to be the best place in Europe to innovate which is why we have invested in this new Centre to capitalise on the North East’s expertise in medicines manufacturing and strengthen the UK’s position as a global leader in life sciences. As part of our successful Catapult network, the centre will bridge the gap between business and academia and help to turn great ideas into commercial reality.”
Steve Bagshaw, CEO of FUJIFILM Diosynth Biotechnologies said: “The National Biologics Manufacturing Centre will provide a valuable resource for the biologics sector in the UK. The centre will help the UK capture more of the expanding global market in high value, high quality manufacture of biologic medicines and make an important contribution to equipping the UK workforce to meet the challenges faced in this sector”.
Chris Dowle, Director of Biologics at CPI added: “CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. Utilising the new Centre we will help companies to commercialise ideas and take them to market faster and with less risk. We are already underway with a number of projects which are helping UK companies prove their technologies in an industrially relevant environment.”
Ruth McKernan, Chief Executive of Innovate UK, said: “This new biologics manufacturing facility will be an important addition to CPI’s world-class capabilities in high value manufacturing. It will also work closely with our ground-breaking three healthcare Catapults and keep the UK at the forefront of a sector we have long excelled in.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance